Link Pharma Chem Ltd (LINKPH) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Link Pharma Chem Ltd on NSE and BSE, with an AI summary of each filing.
We herewith submit Non Applicability of Regulation 23(9) of SEBI (LODR) Regulations, 2015 on Disclosure of related party transactions for the Half year ended on 30th September, 2026.
Others (Uncategorized) · 03 Nov 2026, 6:53 pm
Link Pharma Chem: Exemption from Related Party Disclosures Link Pharma Chem Ltd. announced that Regulation 23(9) of SEBI (LODR) Regulations, 2015—mandating related party transaction disclosures for the half-year ended 30th Sep'26—is not applicable to the company. Pursuant to Regulation 15(2), the company remains exempt from key corporate governance provisions as its paid-up equity share capital does not exceed Rs. 10 crore and its net worth does not exceed Rs. 25 crore as of the last day of the previous financial year.
Unaudited Financial results of the Board meeting held on 3rd November, 2026
Financial Result · 03 Nov 2026, 6:27 pm
Link Pharma Chem Reports Q2 FY27 Net Loss Amid Revenue Decline Link Pharma Chem posted a net loss of Rs 22.31 lakhs for the quarter ended 30th Sep'26, down from a net profit of Rs 1.56 lakhs in 30th Sep'25 and Rs 31.83 lakhs in 30th Jun'26. Revenue from operations fell 15.28% YoY to Rs 533.13 lakhs compared to Rs 629.32 lakhs in the corresponding prior-year quarter. For H1 ended 30th Sep'26, net profit declined 77.21% YoY to Rs 9.52 lakhs on flattish revenue of Rs 1,409.97 lakhs. Basic EPS stood at negative Rs 0.50 for the quarter.
Board meeting outcome of Board Meeting held on 3rd November, 2026
Outcome · 03 Nov 2026, 6:16 pm
Link Pharma Chem Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 533 (-15.3% YoY | -39.2% QoQ) ■ EBITDA: 19.4 (-43.2% YoY | -57.6% QoQ) ■ EBITDA Margin (%): 3.6 (-179 bps YoY | -157 bps QoQ) ■ PAT: -22.3 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -0.50 (Profit to Loss YoY | Profit to Loss QoQ)
Link Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Intimation · 03 Nov 2026, 5:30 am
Link Pharma Chem Board to Consider Q2 FY27 Results on 3rd Nov'26 Link Pharma Chem Ltd has scheduled a Board of Directors meeting on 3rd Nov'26 to consider and approve the unaudited financial results for the quarter and half-year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for designated persons has been closed since 1st Oct'26 and will reopen 48 hours following the declaration of the financial results.
Disclosure order Regulation 30 read with Part A of Schedule III of SEBI Regulation 2015 order received from GST Appellate authority, Tribunal , Vadodara FY 2021-22.
Others (Uncategorized) · 13 Oct 2026, 11:10 pm
Link Pharma Chem Receives Favorable GST Appellate Order Reducing Tax and Penalty Demands Link Pharma Chem received an order on 12th Oct'26 from the GST Appellate Authority, Tribunal Vadodara, regarding FY 2021-2022 issues concerning GSTR-1 vs GSTR-3B mismatches and excess ITC claims. The authority substantially reduced the final GST demand from Rs. 1,32,94,322 to Rs. 16,29,852, alongside lowering the penalty from Rs. 13,29,433 to Rs. 2,05,605. Management confirmed there is no material impact on operations and plans to appeal the remaining demand, penalty, and interest with the appropriate authority.
Re-appointment of Mr. Satish G. Thakur as Whole Time Director for 3 years.
Change in Management · 21 Aug 2026, 1:45 am
Link Pharma Chem: Chairman & Whole-time Director Re-appointed Link Pharma Chem (BSE: 524748) has re-appointed Satish G. Thakur (DIN: 00292129) as Chairman and Whole-time Director for a three-year term, effective from 24th Jun'26. The resolution was passed at the AGM on 20th Aug'26. Mr. Thakur has been with the company since its inception, possesses over 43 years of industry experience, and is the father of Managing Director, Rishikesh Thakur. This decision confirms leadership continuity at the highest level of the company.
Re-appointment of Mr. Rishikesh Thakur as Managing Director of the Company for 3 years.
Change in Management · 21 Aug 2026, 1:43 am
Link Pharma Chem Re-appoints Rishikesh Thakur as Managing Director Link Pharma Chem Ltd. announced the re-appointment of Mr. Rishikesh Thakur as Managing Director for a three-year term, effective from 24th Sep'26. The decision was approved at the company's AGM on 20th Aug'26. Mr. Thakur, who is the son of Chairman Mr. Satish G. Thakur, has over 15 years of experience in the chemical industry, covering manufacturing, R&D, and business development. This move signals leadership continuity for the company.
Voting Results pursuant to clause 44(3) of SEBI LODR Regulation,2015 and Scrutinizer''s report for 41st Annual General Meeting of the Company.
Annual General Meeting · 21 Aug 2026, 1:26 am
Voting Results pursuant to clause 44(3) of SEBI LODR Regulations, 2015, and Scrutinizer''s report for 41st Annual General Meeting of the Company.
Annual General Meeting · 21 Aug 2026, 1:13 am
Summary proceeding of 41st Annual General Meeting of the Company.
Annual General Meeting · 21 Aug 2026, 12:27 am
Unaudited Financial results of the Company for quarter ended June 30, 2026.
Financial Result · 05 Aug 2026, 8:05 pm
Link Pharma Chem Q1 FY27 Net Profit Declines 20.8% YoY Link Pharma Chem reported a 20.8% YoY decline in net profit to ₹31.83 for the quarter ended 30th Jun'26, down from ₹40.19 in the prior year period. Revenue from operations increased by 12.2% YoY to ₹876.84. However, profit before tax fell by 23.7% YoY to ₹38.87, impacted by a 40.2% surge in the cost of materials consumed. On a QoQ basis, the company swung to profit from a loss of ₹40.86 in the previous quarter, with revenue growing 33.1%. EPS for the quarter stood at ₹0.72.
Outcome of Board Meeting held on 05th August, 2026.
Outcome · 05 Aug 2026, 7:49 pm
Link Pharma Chem Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 877 (+12.2% YoY | +33.1% QoQ) ■ EBITDA: 45.6 (-29.1% YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 5.2 (-303 bps YoY | Loss to Profit QoQ) ■ PAT: 31.8 (-20.8% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.72 (-20.9% YoY | Loss to Profit QoQ)
Intimation regarding dispatch of letter containing web link of Annual Report 2025-2026 pursuant to Regulation 36(1)(b) of SEBI (LODR) Regulations, 2015.
Annual Report · 29 Jul 2026, 12:01 am
Link Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Unaudited Financial results ....
Intimation · 05 Aug 2026, 5:30 am
Link Pharma Chem Board Meeting Set for Q1 Results Link Pharma Chem (BSE: 524748) has scheduled a Board of Directors meeting on 05 Aug'26 to consider and approve the unaudited financial results for the quarter ended 30 Jun'26. In compliance with SEBI regulations, the trading window for designated persons has been closed from 01 Jul'26. The window will reopen 48 hours after the financial results are publicly declared.
Submission of Annual Report for the financial year 2025-2026 and Notice convening the 41st Annual General Meeting of the Company under Regulation 34 of the SEBI (Listing Obligations and ....
Others (Uncategorized) · 27 Jul 2026, 9:44 pm
Notice of 41st Annual general Meeting of the Company Scheduled To be held on Thursday, 20th August, 2026 At 11:30 A.M.(IST).
Annual General Meeting · 27 Jul 2026, 9:10 pm
Non-Applicability of Regulation 24A of SEBI (LODR) Regulations, 2015 for Non submission of Annual Secretarial Compliance Certificate for year ended 31st March, 2026.
Others (Uncategorized) · 22 May 2026, 2:33 am
Link Pharma Chem Claims Exemption from SEBI Regulation 24A for FY26 Link Pharma Chem Ltd. (BSE: 524748) has informed the exchange on 21st May'26 that Regulation 24A of the SEBI (LODR) Regulations, 2015, is not applicable to the company for the financial year ended 31st Mar'26. The company cites Regulation 15(2), which exempts entities with paid-up equity capital not exceeding ₹10 crores and net worth not exceeding ₹25 crores as of the previous financial year's last day. Therefore, it is not required to submit the Annual Secretarial Compliance Report.
Non Applicability of Regulations 23(9) of SEBI (LODR) Regulations 2015 on Disclosure of Non Applicability of reporting of Related Party Transactions for the Half year ended on 31st March, 2026.
Others (Uncategorized) · 22 May 2026, 2:14 am
Link Pharma Chem: Exempt from RPT Disclosures for H2FY26 Link Pharma Chem Ltd. (BSE: 524748) announced it is not required to disclose Related Party Transactions (RPTs) for the half-year ended 31 Mar'26. This exemption is under Regulation 15(2) of SEBI (LODR) Regulations, as its paid-up equity share capital is below Rs. 10 Crore and net worth is under Rs. 25 Crore as of the last financial year. Consequently, corporate governance provisions, including Regulation 23(9) on RPTs, do not apply to the company.
Re-appointment of Mr. Rishikesh S. Thakur as Managing Director of the Company for 3 years.
Change in Management · 22 May 2026, 1:55 am
Link Pharma Chem Re-Appoints Rishikesh Thakur as Managing Director Link Pharma Chem's board approved the re-appointment of Mr. Rishikesh Thakur as Managing Director on 21 May'26. The new three-year term is effective from 24 Sep'26, pending shareholder approval at the next AGM. Mr. Thakur, who holds a B.Eng in Polymer, has over 15 years of experience in the chemical business, including manufacturing, R&D, and business development. He is the son of Chairman & Whole-time Director, Mr. Satish G. Thakur, reinforcing management continuity.
Re-appointment of Mr. Satish G. Thakur as Whole time Director for 3 years.
Change in Management · 22 May 2026, 1:54 am
Link Pharma Chem: Chairman & Whole-time Director Re-appointed Link Pharma Chem's board approved the re-appointment of Mr. Satish G. Thakur as Chairman and Whole-time Director on 21st May'26. The new three-year term is effective from 24th Jun'26, subject to shareholder approval at the next AGM. Mr. Thakur, who has over 43 years of industry experience, is associated with the company since its incorporation. He is the father of the company's Managing Director, Mr. Rishikesh Thakur.
Audited Financial Results for the Quarter and year ended 31st March, 2026 along with Statutory Auditor''s Repot thereon.
Outcome · 22 May 2026, 1:30 am
Link Pharma Chem Reports Q4FY26 Net Loss and Reappoints Key Management For the quarter ended 31st Mar'26, Link Pharma Chem reported a net loss of Rs 40.86 lakhs, a decline from a profit of Rs 6.82 lakhs QoQ but an improvement from a loss of Rs 35.02 lakhs YoY. Revenue from operations for Q4FY26 was Rs 658.88 lakhs, down 2.7% QoQ and up 2.2% YoY. For the full year FY26, the company posted a net profit of Rs 7.69 lakhs, recovering from a loss of Rs 102.73 lakhs in FY25. The Board reappointed key management and auditors.
Audited Financial Results of the Company for the quarter and year ended March 31, 2026 along with Statutory Auditor''s Report thereon.
Financial Result · 22 May 2026, 1:14 am
Link Pharma Chem Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 659 (+2.2% YoY | -2.2% QoQ) ■ EBITDA: -23.9 (-7.4% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -3.6 (-17 bps YoY | Profit to Loss QoQ) ■ PAT: -40.9 (-16.7% YoY | Profit to Loss QoQ) ■ EPS (INR): -0.92 (-16.5% YoY | Profit to Loss QoQ)
Link Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve Audited Financial results ....
Intimation · 21 May 2026, 5:30 am
Link Pharma Chem Board Meeting Set for Q4 & FY26 Results Link Pharma Chem (BSE: 524748) has scheduled a Board of Directors meeting on 21st May'26. The agenda includes the consideration and approval of the audited financial results for the quarter and financial year ended 31st Mar'26. In compliance with insider trading regulations, the trading window for designated persons has been closed since 01st Apr'26 and will reopen 48 hours after the results are declared.
We herewith submit unaudited financial result for the quarter and nine months ended on 31st December, 2025
Financial Result · 14 Feb 2026, 11:42 pm
Link Pharma Chem Q3FY26 Results Show Revenue Growth, Turns to Profit YoY Link Pharma Chem reported a PAT of ₹6.82 lakh for Q3FY26, a significant turnaround from a loss of ₹66.71 lakh in Q3FY25. Revenue from operations grew 26.1% YoY to ₹6.73 crore. On a QoQ basis, PAT increased by 337% from ₹1.56 lakh, while revenue rose 7.0%. For the nine months ending 31 Dec'25, the company posted a profit of ₹48.55 lakh, reversing a loss of ₹67.71 lakh YoY, with revenue climbing 9.8% YoY to ₹20.84 crore. EPS for Q3 stood at ₹0.15.
We herewith submit unaudited financial result for the quarter and Nine months ended on 31st December, 2025
Outcome · 14 Feb 2026, 10:21 pm
Link Pharma Chem Ltd. - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakhs) ■ Revenue: 673 (+26.1% YoY | +7.0% QoQ) ■ EBITDA: 69.6 (+525.1% YoY | +104.3% QoQ) ■ EBITDA Margin (%): 10.3 (+826 bps YoY | +493 bps QoQ) ■ PAT: 6.8 (Loss to Profit YoY | +337.2% QoQ) ■ EPS (INR): 0.15 (Loss to Profit YoY | +400.0% QoQ)